Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 405-415

  Copland, Ian B ^a   Jolicoeur, E Marc ^b   Gillis, Marc Antoine ^b   Cuerquis, Jessica ^a   Eliopoulos, Nicoletta ^a   Annabi, Borhane ^c   Calderone, Angelo ^b   Tanguay, Jean Francois ^b   Ducharme, Anique ^b   Galipeau, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Angiogenesis; Cardiovascular regeneration; Cell therapy; Erythropoietin; Mesenchymal stromal cells

Indexed keywords

ERYTHROPOIETIN; MATRIGEL; RETROVIRUS VECTOR; SODIUM CHLORIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BRAIN INFARCTION SIZE; CAPILLARY DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; GENETIC ENGINEERING; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CAPILLARY; HEMODYNAMICS; HISTOLOGY; IMMUNOPHENOTYPING; MESENCHYME CELL; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGENERATION; STROMA CELL; SURVIVAL;

EID: 48749113106     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn090     Document Type: Article

References (39)

1. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233-1247.
2. Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J 2003;4:92-96.
3. Caplice NM, Gersh BJ, Alegria JR. Cell therapy for cardiovascular disease: what cells, what diseases and for whom? Nat Clin Pract Cardiovasc Med 2005;2:37-43.
4. Wang Y, Haider HK, Ahmad N, Xu M, Ge R, Ashraf M. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 2006;40:736-745.
5. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
6. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73:1919-1925 (Discussion 1926).
7. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95.
8. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 2007;180:45-66.
9. Muller-Ehmsen J, Krausgrill B, Burst V, Schenk K, Neisen UC, Fries JW et al. Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 2006;41:876-884.
10. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000;102:2255-2261.
11. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-291.
12. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
13. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005;65:719-727.
14. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Yang N et al. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl Int 2007;20:174-183.
15. Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, LaMarca HL et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 2007;35:640-652.
16. Eliopoulos N, Al-Khaldi A, Crosato M, Lachapelle K, Galipeau J. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 2003;10:478-489.
17. Meriane M, Duhamel S, Lejeune L, Galipeau J, Annabi B. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells 2006;24:2557-2565.
18. Frevert CW, Wong VA, Goodman RB, Goodwin R, Martin TR. Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 1998;213:41-52.
19. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther 2003;10:621-629.
20. Drapeau J, El-Helou V, Clement R, Bel-Hadj S, Gosselin H, Trudeau LE et al. Nestin-expressing neural stem cells identified in the scar following myocardial infarction. J Cell Physiol 2005;204:51-62.
21. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003;35:685-694.
22. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
23. Gosselin H, Qi X, Rouleau JL. Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction. Can J Physiol Pharmacol 1998;76:53-62.
24. Copland I, Sharma K, Lejeune L, Eliopoulos N, Stewart D, Liu P et al. CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. Exp Hematol 2008;36:93-103.
25. Hermitte F, Brunet de la Grange P, Belloc F, Praloran V, Ivanovic Z. Very low 02 concentration (0.1%) favors G0 return of dividing CD34+ cells. Stem Cells 2006;24:65-73.
26. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002;20:485-492.
27. Yoshimura A, Lodish HF. In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130. Mol Cell Biol 1992;12:706-715.
28. Miura O, Nakamura N, Ihle JN, Aoki N. Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor. J Biol Chem 1994;269:614-620.
29. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;5:347-355.
30. Iwatsuki K, Endo T, Misawa H, Yokouchi M, Matsumoto A, Ohtsubo M et al. STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. J Biol Chem 1997;272:8149-8152.
31. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
32. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685.
33. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
34. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
35. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-926.
36. Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther 2005;5:25-35.
37. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-379.
38. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006;24:1095-1103.
39. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007;67:9142-9149.